RSS Feed
Search Ask-Cato.com
Tags
adverse events biologics biosimilar biotech cancer Cato BioVentures Cato Research CDER clinical investigator clinical research clinical trials CMC conference CROs DIA drug development eCTD efficacy FDA funding GlobalSubmit guidance Health Canada IND in vitro diagnostics labeling manufacturing marketing application medical devices NDA NIH nonclinical research oncology Phase 1 Phase 2 postmarketing protocol regulatory affairs safety statistical analysis toxicology transparency venture capital warning letters webinarCategories
- Clinical Trials (52)
- Conferences and Meetings (34)
- eCTD (26)
- FDA (71)
- Guest Posts (5)
- Health Canada (6)
- Industry News (56)
- Project Management (1)
- Publications (7)
- Regulatory Strategy (36)
- Social Media (6)
- Statistics (9)
- Uncategorized (1)
- Venture Capital (10)
- Webinars (24)
Tag Archives: NIH
Fifth China Medicinal Biotech Forum – Conference Recap
I recently returned from the Fifth China Medicinal Biotech Forum held in Beijing, China from 07-09 November 2011. The purpose of this conference was to update graduate students in China on the latest trends in biotechnology. This forum also allowed … Continue reading
Posted in Clinical Trials, Conferences and Meetings
Tagged biologics, biosimilar, biotech, China, clinical research, clinical trials, conference, DNA, efficacy, FDA, gene therapy, immuno, manufacturing, monoclonal antibody therapy, NIH, Phase 1, recombinant proteins, safety
Comments Off
Bridging the Valley of Death: Bringing New Drugs from the Bench to the Clinic
To bring a new medicine to the stage of clinical trial testing requires on the order of $500,000 to one million dollars and then seven to ten years of clinical trials and around $800 million dollars before getting to market. … Continue reading
Posted in Clinical Trials, Venture Capital
Tagged biotech, cancer, Cato BioVentures, clinical trials, CROs, drug development, funding, NIH, Phase 1, Phase 2, preclinical, toxicology, venture capital
Comments Off
Conference Recap – 2011 Society of Toxicology Annual Meeting
The Society of Toxicology’s (SOT) 50th Anniversary Annual Meeting was held on 05-10 March 2011 in Washington, DC. Several members of Cato Research’s Nonclinical Sciences Development group were amongst the more than 7,000 toxicologists from 50 countries in attendance this … Continue reading
Posted in Conferences and Meetings
Tagged FDA, Margaret Hamburg, NIH, nonclinical research, preclinical, safety, toxicology
Comments Off
Diabetes Research Strategic Plan
The media continually alerts us to the epidemic of diabetes in the world. Diabetes is the seventh leading cause of death. Worldwide in 2007 there were 246 million people diagnosed with diabetes, and an additional 79 million people are at … Continue reading
Posted in Clinical Trials, Industry News
Tagged biomarkers, clinical research, clinical trials, diabetes, guest post, NIH, patient recruitment
Comments Off
Therapeutics for Rare and Neglected Diseases – How Rare is Rare?
The U.S. National Institutes of Health (NIH) classifies a rare disease as affecting less than 200,000 individuals in the United States. As insignificant as this classification may sound, collectively there are more than 25 million people in the United States … Continue reading
Posted in Clinical Trials, Regulatory Strategy
Tagged analytical testing, biomarker, clinical trials, dos, exclusivity, FDA, IND, NIH, novel therapeutic, Orphan Drug Designations, tax credit, toxicology
Comments Off
